Status:
COMPLETED
Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborating Sponsors:
Sanofi
Bristol-Myers Squibb
Conditions:
Atherosclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypa...
Detailed Description
Saphenous vein graft disease remains a major limitation of coronary artery bypass graft surgery (CABG). The process of saphenous vein intimal hyperplasia is mediated by platelet aggregation and begins...
Eligibility Criteria
Inclusion
- Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.
Exclusion
- Emergency surgery
- Valve surgery
- Redo CABG
- Left ventricle ejection fraction \< 25%
- Serum creatinine \> 130 µmol/L
- Preoperative use of clopidogrel (with the exception of the current admission)
- Preoperative use of warfarin; allergy to aspirin or clopidogrel.
- History of cerebrovascular accident
- History of severe liver disease
- Morbid obesity
- Current malignancy
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00228423
Start Date
May 1 2006
End Date
July 1 2009
Last Update
April 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7